Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Heat Biologics Stock Is a Worthwhile, Speculative Bet

By Chris Lau, InvestorPlace Contributor

Heat Biologics has a partnership with Bristol-Myers in developing a cancer drug. If things continue to progress positively, HTBX stock could climb higher.

Why Xenetic Biosciences Just Surged 28 Percent

By Chris Lau, InvestorPlace Contributor

Xenetic Biosciences surged once again on a spike in volume. Could XBIO stock rally more and hold on to gains this time around?

GlycoMimetics Stock Has Substantial Upside

By Chris Lau, InvestorPlace Contributor

GlycoMimetics reported no surprises and even beat consensus estimates on earnings. The company has many drugs in clinical trials for treating cancer, AML and MM.

What to Do After Cutera Stock Fell 16.7%

By Chris Lau, InvestorPlace Contributor

CUTR stock has reached attractive levels, as it has a strong, new product, and its investments will improve its business. Value investors should look to buy shares of Cutera.

Protagonist Stock Jumps 58% After Re-Review of Test Results

By Chris Lau, InvestorPlace Contributor

A re-review of the PTG-100 results undid the bad news of a discontinuation of Protagonist's clinical study. If the FDA allows the company to run Phase 2/3 studies for PTG-100, then the stock will continue its bounce higher.

Load More